UBS Group’s Eterna Therapeutics ERNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $61 | Buy |
+19
| New | +$86 | ﹤0.01% | 10914 |
|
|
2026
Q2 | – | Sell |
-849
| Closed | -$4.22K | – | 10595 |
|
|
2026
Q1 | $4.22K | Buy |
849
+825
| +3,438% | +$13.2K | ﹤0.01% | 8961 |
|
|
2025
Q4 | $720 | Buy |
+24
| New | +$817 | ﹤0.01% | 9836 |
|
|
2025
Q3 | – | Sell |
-22
| Closed | -$1.01K | – | 10459 |
|
|
2025
Q2 | $1.01K | Sell |
22
-11
| -33% | -$791 | ﹤0.01% | 9688 |
|
|
2025
Q1 | $2.22K | Sell |
33
-12
| -27% | -$1.48K | ﹤0.01% | 9377 |
|
|
2024
Q4 | $4.96K | Sell |
45
-178
| -80% | -$48.3K | ﹤0.01% | 8710 |
|
|
2024
Q3 | $87.8K | Buy |
+223
| New | +$143K | ﹤0.01% | 6452 |
|
|
2024
Q2 | – | Sell |
-2
| Closed | -$1.78K | – | 9665 |
|
|
2024
Q1 | $1.78K | Buy |
+2
| New | +$1.38K | ﹤0.01% | 8051 |
|
|
2023
Q4 | – | Hold |
0
| – | -$229 | – | 9455 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8677 |
|
|
2023
Q2 | – | Sell |
-10
| Closed | -$13.1K | – | 9097 |
|
|
2023
Q1 | $13.1K | Buy |
+10
| New | +$15K | ﹤0.01% | 7413 |
|
|
2022
Q4 | – | Sell |
-2
| Closed | -$3K | – | 10815 |
|
|
2022
Q3 | $3K | Hold |
2
| – | – | ﹤0.01% | 9528 |
|
|
2022
Q2 | $10K | Hold |
2
| – | – | ﹤0.01% | 7954 |
|
|
2022
Q1 | $28K | Hold |
2
| – | – | ﹤0.01% | 7066 |
|
|
2021
Q4 | $68K | Buy |
2
+1
| +100% | +$54.4K | ﹤0.01% | 6647 |
|
|
2021
Q3 | $71K | Buy |
+1
| New | +$86.3K | ﹤0.01% | 6077 |
|
|
2021
Q2 | – | Hold |
0
| – | -$2K | – | 9478 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 8609 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7992 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 8092 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 7753 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7756 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8177 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7465 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6940 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6035 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7473 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6692 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6568 |
|
|
2018
Q1 | – | Sell |
-1
| Closed | -$83.8K | – | 6348 |
|
|
2017
Q4 | $32K | Buy |
+1
| New | +$79K | ﹤0.01% | 6184 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$104K | – | 6179 |
|
|
2017
Q2 | $57K | Buy |
+1
| New | +$108K | ﹤0.01% | 5553 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7168 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7405 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7400 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7322 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 7302 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8002 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 7262 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7686 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7479 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 8141 |
|
Other funds holding ERNA
UBS Group's ERNA Position: Q3 2026 in Review
UBS Group opened a new position in Eterna Therapeutics (ERNA) in Q3 2026: 19 shares worth $61. The stake represents ﹤0.01% of the portfolio and ranks #10914 among its holdings. This is a return to the name: UBS Group previously reported a position in ERNA as recently as Q1 2026.
UBS Group first reported a position in ERNA in Q2 2017 and has held it in 16 quarters since. The position peaked at $87.8K in Q3 2024. 7 funds tracked by Wall St. Rank hold ERNA as of Q3 2026.
- UBS Group held 19 shares of Eterna Therapeutics worth $61 as of Q3 2026.
- Eterna Therapeutics was a new UBS Group position in Q3 2026.
- Eterna Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10914 holding.
- UBS Group first reported a position in Eterna Therapeutics in Q2 2017 and has held it in 16 quarters since.
- UBS Group's Eterna Therapeutics position peaked at $87.8K in Q3 2024.
- 7 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.